Company Analysis

QuidelOrtho Corporation (QDEL)

Nasdaq: QDEL · In Vitro & In Vivo Diagnostic Substances · San Diego, CA · filing with the SEC since 2022
Grade4.8
◀ Past 5.8● Present 5.0▶ Future 3.6

The company now

QuidelOrtho Corporation is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in San Diego, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-28, it reported revenue of $2.7 billion and a loss of $1.1 billion (its filed statements).

From its filings and filed figures; the desk's account of it is not written yet.

Where the revenue comes from

fiscal 2025, as filed

Revenue by region, fiscal 2025

RegionFiscal 2025Fiscal 2024Share of revenue
Domestic$1.44B$1.57B52.6%
Foreign$1.29B$1.21B47.4%

As tagged in its annual report (Form 10-K, filed Feb 19, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.

The desk's written account of this company, its Past, Present and Future, is not on file yet.

How the company works

The desk has not read this company's annual report yet.

The record in brief

The desk has not written this company's report yet.

SI Assistanton QDEL · research, not advice